Arch Esp Urol 2017 Jul;70(6):561-569
Servicio de Urología. Hospital Universitario Puerta del Mar. Cádiz. España.
J Manag Care Pharm 2008 Apr;14(3):291-301
Xcenda, LLC, Cincinnati, OH 45255, USA. anna.dsouza
Background: Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB). Tolterodine and oxybutynin are commonly prescribed drugs for OAB treatment that exert their beneficial effect by suppressing bladder muscle contractions. However, high discontinuation rates have been observed for these drugs in clinical trials, as well as in real-world settings, in part due to adverse effects. Read More
BJU Int 2007 Apr 20;99(4):836-44. Epub 2006 Dec 20.
Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinburg School of Medicine, Evanston IL, USA.
Objective: To assess health-related quality-of-life (HRQoL) and safety with the oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA) in the Multicentre Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin (MATRIX) study, as HRQoL measurements are increasingly important in evaluating pharmacotherapy for overactive bladder (OAB).
Patients And Methods: This randomized, open-label, community-based study enrolled 2878 participants aged >/=18 years who had been given a diagnosis of OAB. The 327 study sites were representative of various practice types. Read More
Int J Clin Pract 2008 Jan;62(1):167-70
Department of Urology, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.
Overactive bladder (OAB) syndrome affects millions of people worldwide. In addition to adversely affecting quality of life, the direct and indirect costs in managing patients with OAB incur a substantial financial burden on health services. Among the approved anticholinergics for treating OAB, oxybutynin is the most extensively studied drug in clinical trials. Read More
Arch Esp Urol 2018 Jun;71(5):502-505
Servicio de Urología. Hospital de Poniente. El Ejido. Almería. España.
The transdermal route for administration of anticholinergic drugs can provide efficacy with less systemic adverse effects. The transdermal oxybutynin patch (OXYTDS) offers advantages over oral administration for patients treated for Overactive bladder (OAB) syndrome. The limited evidence on the OXY-TDS patch application areas of the skin, makes difficult counseling patients who require a change to skin zones other than those recommended by the manufacturer. Read More